Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive’s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
Legend Biotech has terminated its phase 1 clinical trial for LB1901, an investigational autologous anti-CD4+ chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of adults with relapsed/refractory T-cell lymphoma, according to an SEC filing.
Sarepta Therapeutics’ SRP-9001 (delandistrogene moxeparvovec), an investigational gene therapy for Duchenne muscular dystrophy (DMD) being developed in partnership with Roche, demonstrated improvements on significant functional outcomes with a consistent safety profile, according to newly presented data from multiple studies.
Myrtelle’s gene therapy rAAV-Olig001-ASPA has shown efficacy and safety in patients with Canavan disease, with improvements in white matter and myelin, according to updated data from a phase 1/2 trial (NCT04833907).
The FDA has cleared SCG Cell Therapy’s investigational new drug application for their T-cell receptor (TCR) T cell therapy SCG101 for hepatitis B virus (HBV)-related liver cancer.
The cGMP manufacturing facility in Houston will support the company's cell therapy oncology pipeline. Its completion also addresses a citation in a clinical hold communication received from the FDA.
The collaboration will leverage Mogfrify's cellular reprogramming platform and utilize Astella's expertise in AAV based genetic medicine in an attempt to identify combinations of transcription factors involved in cell differentiation to generate new cochlear hair cells.
Accelerating the development of ViaCyte's VX-880, an investigational cell therapy for Type 1 Diabetes seen as having curative potential, is the focal point of Vertex's plans with the acquisition.
Solvias expects the acquisition to help them meet the pharmaceutical industry's growing need for cell and gene therapy testing.
LG Chem plans to advance the development of CAR-T cell treatments for solid tumors with clinical and commercial rights to MaxCyte's Flow Electroporation technology and ExPERT platform.
ACT Therapeutics expects that the patnership will help accelerate the development of treatments targeting refractory and intractible solid cancers.
The company will collaborate the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute, and will focus its research on the 3 largest genetic segments of arrhythmogenic cardiomyopathy.